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Purpose: To assess the extent of variation in radiosensitivity between individuals, gender-related
dissimilarity and impact on the association with single nucleotide polymorphisms (SNPs).
Materials and methods: Survival curves of 152 fibroblast cell strains derived from both gender were
generated. Individual radiosensitivity was characterized by the surviving fraction at 2 Gy (SF2). SNPs in
10 radiation responsive genes were genotyped by direct sequencing.
Results: The wide variation in SF2 (0.12–0.50; mean = 0.33) was significantly associated with 3 SNPs:
TP53 G72C (P = 0.007), XRCC1 G399A (P = 0.002) and ATM G1853A (P = 0.01). Females and males differed
significantly in radiosensitivity (P = 0.004) that impacted genetic association where only XRCC1 remained
significant in both gender (P < 0.05). Meanwhile, discordant association was observed for TP53 that
was significant in females (P = 0.012) and ATM that was significant in males (P = 0.0006). When
gender-specific SF2-mean (0.31 and 0.35 for females and males; respectively) was considered, further
discordance was observed where XRCC1 turned out not to be associated with radiosensitivity in males
(P > 0.05).
Conclusions: Although the variation in individual radiosensitivity was associated with certain SNPs,
gender bias for both endpoints was evident. Therefore, assessing the risk of radiation exposure in females
and males should be considered separately in order to achieve the ultimate goal of personalized radiation
medicine.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 119 (2016) 236–243
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nd/4.0/).Ionizing radiation (IR) is ubiquitous in nature and living organ-
isms are continuously exposed to variable level of low radiation
doses from natural radioactive background and escalating doses
from medical practices and industrial applications [1]. Although
IR has many beneficial applications in modern life, it might cause
deleterious effects particularly if it has been misused [2–4].
Individuals, however, do not respond equally to similar doses
of IR. Human population heterogeneity in radiosensitivity is
illustrated by rare genetic disorders such as ataxia-telangiectasia
(A-T), Nijmegen breakage syndrome (NBS), NBS-like, ligase IV defi-
ciency (LIG4 syndrome) and ataxia-telangiectasia like disorder
(ATLD). Cells derived from those patients are hypersensitive to IR
due to mutations impacting DNA double-strand break (DSB) recog-
nition, signaling, and repair capacity [5,6]. However mutations arerare and present only in a small percentage of hypersensitive indi-
viduals [7].
To explain the wide range of radiosensitivity, attention is
focused on the more common genetic polymorphic variations
between individuals. Unlike genetic mutations that disrupt the
function of the encoded protein, single nucleotide polymorphisms
(SNPs) may only cause subtle changes that can influence the rate of
mRNA transcription, mRNA stability, its rate of translation to
protein and/or the protein–protein interactions resulting in sub-
optimum protein function leading to different degrees of suscepti-
bility to IR, environmental factors, infectious agents, diseases and
individual response to pharmacological agents [8,9]. Furthermore,
there are variations between human populations, so a SNP allele
that is common in one geographical or ethnic group may be
infrequent in another [10].
The association between SNPs and radiosensitivity in the
general population has not been systematically studied. This is
important because IR poses accentuated health hazard particularly
with the continuous increase in the applications of radiation
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quent increase in the collective doses received by the population
particularly in radiosensitive individuals [11] may cause an
increase in the cumulative deleterious effects in humans which
in its turn may be translated to increase in the long term appear-
ance of certain types of complications and cancers [12]. The main
deterministic and stochastic health effects of radiation exposure
are the induction of toxicity in organs and tissues, neoplastic trans-
formation in addition to potential hereditary consequences [4].
The term ‘‘radiogenomics” has initially been applied to identify
candidate genetic biomarkers to individualize risk of developing
morbidity in radiotherapy patients [13], which gained momentum
with the advent of genome wide association studies [14,15]. Simi-
larly, it seems tempting to hypothesize that ‘‘radiogenomics” can
also apply to individual variations in radiosensitivity in the popu-
lace. Currently health protection policies do not take into account
any contribution of genetic variations to individual risk of radiation
exposure [16]. Such contribution would help to develop more
refined approaches to assess radiation health risk in humans.
In this study, we have explored this hypothesis using 152
fibroblast cell cultures established from normal individuals. Cellu-
lar radiosensitivity was measured by the gold-standard clonogenic
survival assays. Genetic variations were determined by direct
genotyping of 10 selected SNPs in genes known to be involved in
radiation response (CDKN1A (p21) C31A (Ser/Arg) rs1801270,
TP53 (p53) codon G72C (Arg/Pro) rs1042522, HDM2 (MDM2) pro-
moter T309G rs2279744, ATM G1853A (Asp/Asn) rs1801516,
XRCC1 G399A (Arg/Gln) rs25487, XRCC3 G241A (-strand C/T)
(Thr/Met) rs861539, LIG4 (DNA-Ligase 4) C9T (Thr/Ile) rs1805388,
PRKDC (DNA-PKcs) T3434C (-strand A/G) (Ile/Thr) rs7830743,
TGFB1 C10T (Lue/Pro) rs1982073 and XRCC5 (KU80) A2790G 30
UTR rs1051685).Materials and methods
Cell strains and culture conditions
A total of 152 non-transformed fibroblast cell strains were used
from our cell strain collections established from phenotypically
normal individuals. The institutional review board (IRB) has
approved the study. Donors have voluntarily participated and
signed an informed consent. The method of establishing the fibrob-
last cell strains was described elsewhere [17]. Cells were main-
tained in DMEM culture medium supplemented with 15% fetal
bovine serum, 100 units/ml penicillin, and 0.1 mg/ml streptomycin
and incubated at 37 C in 5% CO2 humidified atmosphere.Cellular radiosensitivity measurements
Experiments were carried out using previously described
methodology with minor modifications [18]. Briefly, to minimize
experimental variations due to cell cycle differences, contact-
inhibited cultures were used. Clonogenic survival was assessed
using fixed number of seeded cells (tested + feeder) of 1000 cells/
cm2. Feeder cells, from the same cell strain tested, were irradiated
with a single irradiation dose of 30 Gy (to prevent any cell division)
and seeded in appropriate numbers 24 h before receiving the
tested cells. The tested confluent fibroblast cultures were trypsi-
nized, counted, diluted and seeded in an appropriate number to
yield at least 50 colonies in each of 3 replicated flasks. Irradiation,
with a single dose that ranged between 0 and 4 Gy, was delayed for
4–6 h after plating to allow the cells to attach to the surface of the
flasks. The cells were incubated for 2–3 weeks, then they were
fixed and stained using crystal violet. Colonies of at least 50 cells
were scored as survivors. Three to five independent experiments
were carried out for each cell strain.DNA extraction, amplification and sequencing
DNA was extracted from cultured fibroblasts using Puregene
DNA Purification Kit (Gentra System, Qiagen, Minneapolis, MN,
USA) according to the manufacturer’s instruction. PCR primers of
the selected SNPs are available upon request. Relevant segments
of DNA were amplified by thermal cycling as described previously
[19]. The amplified fragment was directly sequenced using the
DYEnamic ET Dye Terminator Cycle Sequencing Kit (Amersham
Biosciences, Piscataway, NJ, USA) according to the manufacturer’s
instruction, and were run on the MegaBase 1000 sequencer
(Applied Biosystems, Waltham, MA, USA). Sequencing results were
aligned to the corresponding reference sequence and the SNPs
were genotyped using SeqManII sequence analysis software
(DNASTAR Inc., Madison, WI, USA).Irradiation
Irradiation was performed using X-RAD 320 (Precision X-ray,
CT, USA) biological irradiator at a maximum energy of 320 keV fil-
tered with 2 mm Al, and a dose rate of 1.33 Gy/min. In addition to
ionizing chamber (PTW, Freiburg, Germany), the absorbed dose
was also measured using a GAFCHROMIC film, EBT2 model
(International Specialty Products, Wayne, NJ, USA) as described
previously [20].Data analysis
Survival data from replicate experiments were pooled and fitted
to the linear quadratic model of cell killing [SF = exp (aD  bD2),
where a and b are constant and D is the dose], to generate cellular
survival curves. The well-established parameter of the surviving
fraction at 2 Gy (SF2) was used to characterize the radiosensitivity
of each cell strain [21]. SF2 was computed from the whole survival
curve and used as a unique measure of cellular sensitivity to radi-
ation. The mean SF2 of the 152 cell strains was used to separate cell
strains to 2 groups, radiosensitive (cases) and normal (controls).
The association between radiosensitivity groups (SF2), SNPs
genotype and allelic frequency were measured by the odds ratio
(OR) with its 95% confidence interval (95% CI). Significance of OR
was assessed by the Chi-square (v2) test. A P-value of 0.05 or less
is considered statistically significant. The alleles showing statisti-
cally significant (P 6 0.05) association with increased radiosensi-
tivity (decreased SF2) were considered as risk allele and given a
score of 1. Therefore, cell strains homozygous for a risk allele have
a score of 2, heterozygous have a score of 1, while those which do
not harbor the risk allele have a score of zero. The number of risk
alleles for each individual was calculated by summing the scores
of the different SNPs significantly associated with radiosensitivity.
Difference between groups was assessed by the non-parametric
Mann–Whitney Rank Sum test. Correction for multiple compar-
isons was carried out using the Bonferroni method, which indicates
statistical significance when the P-value is lower than the type I
error (0.05) divided by the number of comparisons declared signif-
icant. Statistical analysis was carried out using the SigmaPlot plat-
form (Version 12.5, Systat Software, Inc., San Jose, CA, USA) and the
free online software, Case Control Studies, Institute of Human
Genetics, Helmholtz Center Munich, Germany (http://ihg.gsf.de/
cgi-bin/hw/hwa1.pl).
Results
Subjects and cellular radiosensitivity
The age of the 152 subjects included in this study ranged
between 18 and 79 (median = 48) years old. There were 63 males
and 89 females. The survival curves of the 152 fibroblast cell
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radiosensitivity (Fig. 1, panel A). The SF2 ranged between 0.12
and 0.50 (Fig. 1 panel B) with a mean of 0.33 (SD = 0.089). The
mean SF2 was used to separate the cell strains according to
radiosensitivity to 2 groups: normal (control, SF2 > 0.33, n = 83)
and radiosensitive (cases, SF2 6 0.33, n = 69). The mean SF2 of
the control and the radiosensitive groups were 0.40 (SD = 0.039)
and 0.25 (SD = 0.062); respectively. A gender related differences
in radiosensitivity was observed. The average SF2 of the survival
curves of females donors (SF2 = 0.31, C.I. 95% = 0.019) was slightly
lower than that of males (SF2 = 0.35, C.I. 95% = 0.020). Box plot
analysis of the relationship between SF2 and gender showed lower
median SF2 for females (0.33) than for males (0.36) donors (Fig. 2).
The Mann–Whitney sum rank test showed that differences
between the median SF2 was statistically significant (P = 0.004).Fig. 2. Box plot analysis of the relationship between radiosensitivity (SF2) and
gender of donors. The lines within the boxes represent the median SF2 of females
and males. The lower and the upper boundaries of the box indicate the 25th and the
75th percentiles, respectively. The bars above and below the box indicate the 90th
and 10th percentiles. Data points represent the outliers.SNPs genotypes and alleles analysis
The genotype distribution of the assessed polymorphisms and
its relationship with radiosensitivity (SF2) are given in Fig. 3.
Although a wide range of variations were observed, there were
apparent patterns between the mean SF2 per genotype and the
polymorphisms studied. The pattern was gene dependent. The
CDKN1A C31A and ATM G1853A showed a trend toward increased
radiosensitivity with the presence of the variant genotype. Con-
versely, the TP53 G72C, the XRCC1 G399A, XRCC5 A2790G and
PRKDC T3434C showed a trend toward decreased sensitivity with
the presence of the variant genotype. The remaining SNPs (HDM2
T309G, TGFB1 C10T, XRCC3 G241A, and LIG4 C9T) could hardly
reveale any trend toward dependence of SF2 on genotypes (Fig. 3).
Statistically significant associations between genotypes and
groups of radiosensitivity were observed for TP53 G72C, ATM
G1853A and XRCC1 G399A, particularly when comparing homozy-
gous variants with majority genotypes (Table 1). These associa-
tions were more obvious with the allelic analysis. Both variant
alleles of TP53 72C (Pro) and XRCC1 399A (Gln) were significantly
associated with more radio-resistant (higher SF2) phenotype
[P = 0.007, Odds Ratio = 0.52 (C.I. 95%: 0.33–0.84) and P = 0.002,
Odds Ratio = 0.41 (C.I. 95%: 0.23–0.74); respectively]. In contrast,
the variant allele of ATM 1853A (Asn) was significantly associated
with radio-sensitive (lower SF2) phenotype [P = 0.01, Odds
Ratio = 2.96 (C.I. 95%: 1.24–7.04)]. Borderline (P > 0.05; 60.10)0.
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The alleles that showed statistically significant association with
increased radiosensitivity [majority alleles TP53 G72 (Arg), XRCC1
G399 (Arg) and variant ATM 1853A (Asn)] have been counted to
calculate the total number of risk alleles for each cell strain. The
relationship between the number of risk alleles and SF2 has been
analyzed by Box Plot (Fig. 4). To obtain sufficient numbers for
meaningful analysis, the total risk alleles have been grouped as fol-
lows: 0 + 1, 2, 3, 4, and 5 + 6. Although there were variations, the
median value of SF2 showed a clear trend to decrease (higher
radiosensitivity) with increasing number of risk alleles. The Krus-
kal–Wallis One Way Analysis of Variance on Ranks confirmed this
trend and showed a statistically significant difference in the med-
ian number of risk alleles (ANOVA on ranks: P = 0.012).Discussion
The objective of this study was to evaluate the extent of varia-
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Fig. 3. The relationship between radiosensitivity (SF2) and genotype distribution of the 10 assessed polymorphisms in 152 fibroblast cell strains (gray circles). The open
circles represent the mean SF2 by genotype. The error bars are the standard deviation from the mean.
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assess potential risk of radiation exposure [22]. The presence of dif-
ferences in radiation sensitivity between individuals is expected to
render subjects more or less susceptible to radiation-induced inju-
ries [23]. Thus some individuals may be more vulnerable and are atincreased risk of sustaining acute, short-term reactions or latent,
long-term radiation consequences.
To our knowledge, this is one of the largest cohort of radiation
sensitivity study involving fibroblast cell strains derived from nor-
mal individuals [18,24,25]. The age of donors ranged between 18
Table 1
Genotype and allele frequencies of 10 assessed polymorphisms in 152 individuals who either having normal (controls, SF2 > 0.33) or increased (cases, SF2 6 0.33) cellular
radiosensitivity.
Genetic polymorphism Genotype and allele SF2 n (%) Odds Ratio
(95% CI)
P-value
Cases
(n = 69)
Controls
(n = 83)
CDKN1A (p21) codon 31 C/A (Ser/Arg) rs1801270 C/C 34 (49) 44 (53)
C/A 30 (43) 36 (43) 1.07 (0.55–2.08) 0.82
A/A 5 (07) 3 (04) 2.15 (0.48–9.66) 0.30
C 98 (71) 124 (75)
A 40 (29) 42 (25) 1.20 (0.72–2.00) 0.47
TP53 (p53) codon 72 G/C (Arg/Pro) rs1042522 G/G 32 (46) 21 (25)
G/C 27 (39) 42 (51) 0.42 (0.20-0.87) 0.019
C/C 10 (14) 20 (24) 0.32 (0.12–0.83) 0.017
G 91 (66) 84 (51)
C 47 (34) 82 (49) 0.52 (0.33–0.84) 0.007
HDM2 (MDM2) promoter 309 T/G rs2279744 T/T 22 (32) 30 (36)
T/G 38 (55) 35 (42) 1.48 (0.72–3.03) 0.28
G/G 9 (13) 18 (22) 0.68 (0.25–1.80) 0.43
T 82 (59) 95 (57)
G 56 (41) 71 (43) 0.91 (0.57–1.44) 0.69
ATM codon 1853 G/A (Asp/Asn) rs1801516 G/G 54 (78) 75 (90)
G/A 12 (17) 8 (10) 2.08 (0.79–5.44) 0.12
A/A 3 (04) 0 (0) 9.69 (0.49–191.60) 0.044
G 120 (87) 158 (95)
A 18 (13) 8 (05) 2.96 (1.24–7.04) 0.010
TGFB1 codon 10 C/T (Lue/Pro) rs1982073 C/C 14 (20) 22 (27)
C/T 22 (32) 32 (39) 1.08 (0.45–2.55) 0.86
T/T 33 (48) 29 (35) 1.78 (0.77–4.12) 0.17
C 50 (36) 76 (46)
T 88 (64) 90 (54) 1.48 (0.93–2.36) 0.092
XRCC1 codon 399 G/A (Arg/Gln) rs25487 G/G 53 (77) 50 (60)
G/A 12 (17) 18 (22) 0.62 (0.27–1.43) 0.26
A/A 4 (06) 15 (18) 0.25 (0.07–0.80) 0.014
G 118 (86) 118 (71)
A 20 (14) 48 (29) 0.41 (0.23–0.74) 0.002
XRCC3 codon 241 G/A (-strand C/T) (Thr/Met) rs861539 G/G 30 (43) 28 (34)
G/A 27 (39) 40 (48) 0.63 (0.31-1.28) 0.20
A/A 12 (17) 15 (18) 0.74 (0.29–1.86) 0.53
G 87 (63) 96 (58)
A 51 (37) 70 (42) 0.80 (0.50–1.27) 0.35
XRCC5 (KU80) A2790G 30 UTR rs1051685 A/A 59 (86) 63 (76)
A/G 9 (13) 18 (22) 0.53 (0.22–1.28) 0.15
G/G 1 (01) 2 (02) 0.53 (0.04–6.04) 0.60
A 127 (92) 144 (87)
G 11 (08) 22 (13) 0.56 (0.26-1.21) 0.14
PRKDC (DNA-PKcs) codon 3434 T/C (-strand A/G) (Ile/Thr) rs7830743 T/T 66 (96) 77 (93)
T/C 3 (04) 6 (07) 0.58 (0.14–2.42) 0.45
C/C 0 (0) 0 (0) 1.16 (0.02–59.54) 1.00
T 135 (98) 160 (96)
C 3 (02) 6 (04) 0.59 (0.14–2.41) 0.51
LIG4 codon 9 C/T (Thr/Ile) rs1805388 C/C 60 (87) 71 (86)
C/T 9 (13) 12 (14) 0.88 (0.35–2.25) 0.80
T/T 0 (0) 0 (0) 1.18 (0.02–60.45) 1.00
C 129 (93) 154 (93)
T 9 (07) 12 (07) 0.89 (0.36–2.19) 0.80
Computed using the free online test for association (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl).
240 Gender bias in radiosensitivity & SNPsand 79 with a median age of 48 years. This is the range of age of
major workforce for whom safety and health are important to
prevent the burden of illnesses and injuries [26]. For example, evi-
dence is emerging that radiation exposure may increase long-term
risk of cardiovascular disease [27]. Of particular in this context are
those that can emanate from medical procedures and occupational
radiation exposure [28].
The clonogenic survival of the 152 fibroblast cell strains
revealed a wide range of radiosensitivity that extends to about 4-
fold differences between the most sensitive and the most resistant
(Fig. 1). This presents sizable differences and could imply that
some subjects are more at risk of radiation injuries than others.In addition, gender-related difference in radiosensitivity was
observed (Fig. 2). This suggests gender related variation in
radiosensitivity where women are slightly but significantly more
radiosensitive than men (P = 0.004). The relationship between the
genotypes of the 10 SNPs studied and SF2 showed various trends
indicating increase, decrease and no dependence on radiosensitiv-
ity (Table 1). As tendencies toward increased risk from heterozy-
gous to homozygous genotypes was also observed (Fig. 3), this
implies that harboring two variant alleles have added influence
on radiosensitivity, suggestive of additive model of genetic pene-
trance [29]. This also indicates that not all variant SNPs are risky,
and some of them could be evolutionary advantageous [30].
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ANOVA on ranks: P = 0.012
Fig. 4. Box plot analysis of the relationship between radiosensitivity (SF2) and
number of risk alleles. The lines within the boxes are the median number of risk
alleles. The lower and the upper boundaries of the box indicate the 25th and the
75th percentiles, respectively. The bars above and below the box indicate the 90th
and 10th percentiles. Data points represent the outliers.
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into the relationship between genotypes and phenotypes. This is
particularly true for non-synonymous SNPs where allelic expres-
sion becomes an important tool for integrating genome and tran-
scriptome data to characterize various biological phenomena
[31]. The association observed for TP53 rs1042522 (P = 0.007),
ATM rs1801516 (P = 0.01) and XRCC1 rs25487 (P = 0.002) remains
statistically significant after taking into consideration multiple
comparisons using the Bonferroni correction, which in this case
equals to 0.017. The collective effects of the number of risk allelesTable 2
Allele frequencies and comparison of gender-related associations of 3 SNPs that showed sig
out in two steps: (A) combined mean SF2 = 0.33 (females: cases = 46, control = 43; males: ca
controls = 52; and 0.35 for males: cases = 30, controls = 33).
SNPs Gender Allele frequencies: n (%
Cases
(A) Combined mean SF2
TP53 G72C rs1042522 Females G: 63 (68)
C: 29 (32)
Males G: 28 (61)
C: 18 (39)
ATM G1853A rs1801516 Females G: 86 (93)
A: 6 (7)
Males G: 34 (74)
A: 12 (26)
XRCC1 G399A rs25487 Females G: 77 (84)
A: 15 (16)
Males G: 41 (89)
A: 5 (11)
(B) Gender-related mean SF2
TP53 G72C rs1042522 Females G: 51 (69)
C: 23 (31)
Males G: 34 (57)
C: 26 (43)
ATM G1853A rs1801516 Females G: 70 (95)
A: 4 (5)
Males G: 47 (78)
A: 13 (22)
XRCC1 G399A rs25487 Females G: 62 (84)
A: 15 (16)
Males G: 47 (78)
A: 13 (22)
Computed using the free online test for association (http://ihg.gsf.de/cgi-bin/hw/hwa1.passociated with increased radiation sensitivity [the majority alleles
TP53 G72 (Arg) and XRCC1 G399 (Arg), and the variant allele ATM
1853A (Asn)] showed increased cellular radiosensitivity with
increasing number of risk alleles (Fig. 4). The significant correlation
observed (ANOVA on ranks, P = 0.012) indicates that harboring
higher number of risk alleles has incremental effect on radiosensi-
tivity. This illustrates that cellular radiation response requires the
concerted action of multiple genes and further support the conclu-
sion that radiosensitivity is a complex genetically controlled trait
with the outcome being determined by multitude of additive
effects. These genes could be candidate biomarkers in occupation-
ally, environmentally or medically exposed groups [22] and possi-
ble targets for innovative therapies in radiosensitive individuals.
The gender related discrepancy in radiosensitivity observed in
this study is of particular significance. We have separated allelic
frequencies of males and females of the 3 SNPs that showed statis-
tically significant associations and we have re-tested their associa-
tions with SF2 within each gender. We have observed discordant
association for the 3 SNPs tested (Table 2). Using the combined
SF2 mean of 0.33, the association between radiosensitivity and
XRCC1 rs25487 remained statistically significant (P < 0.05) in both
genders. Meanwhile, discordant association was observed for TP53
rs1042522 that was significant in females (P = 0.012) and ATM
rs1801516 that was significant in males (P = 0.0006). Conse-
quently, we have re-tested the association using gender-specific
SF2 mean (0.31 and 0.35 for females and males; respectively).
TP53 rs1042522 and ATM rs1801516 have maintained the same
results mentioned earlier. While, XRCC1 rs25487 has retained a
near-borderline significant association (precisely, P = 0.0504) in
females, it turned out not to be associated with radiosensitivity
in males (P > 0.05).nificant link with radiosensitivity in the 152 individuals. The comparison was carried
ses = 23, controls = 40), and (B) gender-related mean SF2 (0.31 for females: cases = 37,
) Odds Ratio (95% CI)
P-value
Concordance F/M
Controls
G: 43 (50)
C: 43 (50)
0.46 (0.25–0.84)
0.012
No
G: 41 (51)
C: 39 (49)
0.67 (0.32–1.41)
0.29
G: 82 (95)
A: 4 (5)
1.43 (0.38–5.25)
0.74
No
G: 76 (95)
A: 4 (5)
6.70 (2.01–22.30)
0.0006
G: 59 (69)
A: 27 (31)
0.42 (0.20-0.87)
0.017
Yes
G: 59 (74)
A: 21 (26)
0.34 (0.11–0.98)
0.039
G: 55 (53)
C: 49 (47)
0.50 (0.27–0.94)
0.031
No
G: 35 (53)
C: 31 (47)
0.86 (0.42–1.74)
0.68
G: 99 (95)
A: 5 (5)
1.13 (0.29–4.36)
1.00
No
G: 63 (95)
A: 3 (5)
5.80 (1.56–21.54)
0.0039
G: 74 (71)
A: 30 (29)
0.47 (0.22–1.01)
0.050
No
G: 53 (80)
A: 13 (20)
1.12 (0.47–2.67)
0.78
l).
242 Gender bias in radiosensitivity & SNPsThese are intriguing results and suggest that females and males
are two distinct populations and considering them together as one
group introduces bias in genetic association studies. Although we
do not dispose of mechanistic explanation for these observed dif-
ferences, it is plausible that it may emanate from genetic and phys-
iological dissimilarities between the two genders where gene
regulation and also hormonal factors may play important roles.
This conclusion may imply that women are relatively at higher risk
of sustaining radiation injuries than men. This is plausible as gen-
der related differences in immunity were also observed and attrib-
uted to the sex-specific differences in immune and endocrine
systems [32]. Gender-related differences in radiosensitivity in
human have occasionally been described for certain endpoints
such as proteins expression in preoperative radiotherapy of rectal
cancer patients [33], hematopoietic stem cells (HSCs) [34], and
DNA double-strand breaks damage and repair [35]. In addition,
since some studies have reported individual differences in cellular
radiosensitivity at higher doses [36], we have also computed the
surviving fraction at 4 Gy (SF4) which had essentially recapitulated
the main findings as with SF2.
The projection of these results on clinical radiosensitivity in
radiotherapy patients could be important as many studies have
reported significant associations with genetic polymorphic varia-
tions while other could not ascertain such involvements (see for
examples [19,37–41]). The observed gender-related bias may con-
tribute to the inconsistency observed between studies [42]. The
advent of genome-wide association (GWAS) and copy number
variation (CNVs) studies may further uncover specific genetic dif-
ferences between males and females. These could be of particular
importance for normal tissue complication risk due to gender-
related variation in gene regulation and hormonal factors that
may impact tissular interaction and affect long-term tissue remod-
eling and production of extra-cellular matrix. Therefore, gender-
specific radiosensitivity should be considered as contributing
variable to the development of complications to radiotherapy [43].Conclusions
Although the wide variation in individual radiosensitivity were
significantly associated with TP53 (p53) codon G72C (Arg/Pro)
rs1042522, ATM G1853A (Asp/Asn) rs1801516 and XRCC1 G399A
(Arg/Gln) rs25487, it showed gender-related discrepancies. This
gender bias warren against combining data from males and
females as their radiosensitivity seems to be slightly but signifi-
cantly different. Further attention to gender-related dissimilarities
in various cellular, genomic and clinical endpoints are essential in
order to ascertain the values of biological markers in assessing
individual risk of radiation exposure and progress toward
personalized radiation medicine.Conflict of interest statement
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